Dergiler / Turkish Journal of Medical Sciences / 2008 / Cilt: 38 - Sayı: 3

Second-Line Drug Susceptibilities of Multidrug-Resistant Mycobacterium tuberculosis Isolates in Aegean Region - Turkey

Sayfa
245–250
Yayın Tarihi
2022-11-05
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusions: The results of the study indicate that the high rates of resistance to ethionamide and capreomycin may be a problem in the treatment of patients with MDR-TB; XDR-TB is not yet a serious problem in our region.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim: The emergence of multidrug-resistant tuberculosis (MDR-TB) is increasing, and the standard short-course regimen used for the treatment of TB is likely to be ineffective against MDR-TB, leading to the need for second-line drugs.
📊
Temel Bulgular & Veri:Materials and Methods: In this study, drug susceptibility testing of 40 MDR-TB strains isolated from the Aegean region of Turkey was performed using the BACTEC 460 TB radiometric system.
💡
Sonuç & Katkı:Conclusions: The results of the study indicate that the high rates of resistance to ethionamide and capreomycin may be a problem in the treatment of patients with MDR-TB; XDR-TB is not yet a serious problem in our region.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Mycobacterium tuberculosis · multidrug-resistant tuberculosis (MDR-TB) · second-line drugs

Özet

Aim: The emergence of multidrug-resistant tuberculosis (MDR-TB) is increasing, and the standard short-course regimen used for the treatment of TB is likely to be ineffective against MDR-TB, leading to the need for second-line drugs. In such situations, drug susceptibility testing is necessary to select an appropriate treatment regimen. Unfortunately, there are few studies showing the pattern of the second-line drug resistance in Turkey. We aimed to analyze the resistance to second-line anti-tuberculosis drugs of MDR strains of Mycobacterium tuberculosis isolated from the Aegean region of Turkey. Materials and Methods: In this study, drug susceptibility testing of 40 MDR-TB strains isolated from the Aegean region of Turkey was performed using the BACTEC 460 TB radiometric system. Capreomycin, ethionamide, kanamycin, amikacin, clofazimine and ofloxacin were tested in 1.25 µg/ml, 1.25 µg/ml, 5.0 µg/ml, 1.0 µg/ml, 0.5 µg/ml, and 2.0 µg/ml concentrations, respectively. Results: The results showed that 37.5% of the strains were resistant to ethionamide, 25% to capreomycin, 5% to kanamycin, amikacin and ofloxacin, and 2.5% to clofazimine. One (2.5%) of the 40 MDR-TB cases was defined as extensively drug-resistant tuberculosis (XDR-TB). Conclusions: The results of the study indicate that the high rates of resistance to ethionamide and capreomycin may be a problem in the treatment of patients with MDR-TB; XDR-TB is not yet a serious problem in our region.

Abstract

Aim: The emergence of multidrug-resistant tuberculosis (MDR-TB) is increasing, and the standard short-course regimen used for the treatment of TB is likely to be ineffective against MDR-TB, leading to the need for second-line drugs. In such situations, drug susceptibility testing is necessary to select an appropriate treatment regimen. Unfortunately, there are few studies showing the pattern of the second-line drug resistance in Turkey. We aimed to analyze the resistance to second-line anti-tuberculosis drugs of MDR strains of Mycobacterium tuberculosis isolated from the Aegean region of Turkey. Materials and Methods: In this study, drug susceptibility testing of 40 MDR-TB strains isolated from the Aegean region of Turkey was performed using the BACTEC 460 TB radiometric system. Capreomycin, ethionamide, kanamycin, amikacin, clofazimine and ofloxacin were tested in 1.25 µg/ml, 1.25 µg/ml, 5.0 µg/ml, 1.0 µg/ml, 0.5 µg/ml, and 2.0 µg/ml concentrations, respectively. Results: The results showed that 37.5% of the strains were resistant to ethionamide, 25% to capreomycin, 5% to kanamycin, amikacin and ofloxacin, and 2.5% to clofazimine. One (2.5%) of the 40 MDR-TB cases was defined as extensively drug-resistant tuberculosis (XDR-TB). Conclusions: The results of the study indicate that the high rates of resistance to ethionamide and capreomycin may be a problem in the treatment of patients with MDR-TB; XDR-TB is not yet a serious problem in our region.

🔖

Bu Makaleye Atıf Yap

ÖZKÜTÜK, N., ÖZKÜTÜK, A., GAZİ, H., ÖZBAKKALOĞLU, B., SÜRÜCÜOĞLU, S., COŞKUN, M. (2022). Second-Line Drug Susceptibilities of Multidrug-Resistant Mycobacterium tuberculosis Isolates in Aegean Region - Turkey. Turkish Journal of Medical Sciences, Cilt: 38 - Sayı: 3, 245–250. https://ajindex.com/articles/611818

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (4)

  1. World Health Organization. Anti-tuberculosis drug resistance in the world. Report 3. The WHO/IUATLD Global Project on Antituberculosis Drug Resistance Surveillance. WHO/HTM/TB/ 2004.343. Geneva, Switzerland: WHO; 2004. pp. 21-83
  2. MMWR. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000- 2004. Morb Mortal Wkly Rep 2006 Mar 24; 55(11): 301-5
  3. Pfyffer GE, Bonato DA, Ebrahımzadeh A, Gross W, Hotaling J, Kornblum J et al. Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. J Clin Microbiol 1999; 37: 3179-86
  4. National Committee for Clinical Laboratory Standards. Susceptibility Testing of Mycobacteria, Nocardia, and other aerobic Actinomycetes; Approved Standard, NCCLS document M24-A, Pennsylvania USA, 2003. p. 5.